Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

- Tezampanel Development Targeting Chronic Pain Conditions; Compound

Currently in Phase IIb Clinical Trial for Acute Migraine -

LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a Phase I multiple dose clinical trial to evaluate the safety, tolerability and pharmacokinetics of tezampanel given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. Tezampanel, an AMPA/kainate (AK) receptor antagonist that selectively binds to certain AK receptors to potentially block the transmission of pain signals, has been administered in single doses to more than 300 patients and healthy adults. Data from this multiple dose trial will support the continued development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider expanding the development of tezampanel into additional chronic pain conditions.

The double-blind, placebo-controlled, multiple-dose trial will be conducted at one center in the United States. Approximately 30 healthy male and female volunteers, between the ages of 21 and 55, will be enrolled in sequential, dose-escalating cohorts and receive once-daily subcutaneous doses of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days. These same dose strengths, given as a single dose subcutaneous injection, are currently being evaluated by TorreyPines in a Phase IIb clinical trial of tezampanel for acute migraine.

"We are pleased with our development progress for tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment and we are on track to announce top line results in the fourth quarter of this year. We believe tezampanel represents a potentially new and promising alternative to current treatments for not only migraine but also other pain conditions. Obtaining multiple dose safety and tolerability data will allow us to plan future studies in those chronic painful conditions."

In five Phase IIa, placebo-controlled trials, tezampanel demonstrated proof of concept in multiple pain models. In a placebo and active-controlled clinical trial in patients with acute migraine, the compound, administered intravenously, achieved statistical significance on all primary and secondary endpoints traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia.

About AK Receptor Antagonists

AK receptors are part of the glutamate biological pathway that transmits pain signals to the brain. In addition, these receptors play a critical role in the development of central sensitization phenomena -- a key component of many pain syndromes, including migraine and persistent pain states such as chronic neuropathic pain. AK receptor antagonists selectively bind to certain AK receptors to block transmission of pain signals mediated through the activation of a subtype of glutamate receptors. Because they do not block opioid receptors or constrict blood vessels, the safety profile of AK antagonists may offer important advantages over existing drugs to treat migraine and other pain conditions.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing for reporting clinical trial results for tezampanel, the potential for tezampanel as a treatment for migraine and other pain indications and the potential of TorreyPines Therapeutics' product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from the combined company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics' annual report on Form 10-K for the year ended December 31, 2006 as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/18/2017)... TOKYO , Jan. 18, 2017  Astellas ... , "Astellas" ) today announced its participation in ... access to non-communicable disease (NCD) prevention, diagnostics and ... with 21 other leading pharmaceutical companies and in ... Union for International Cancer Control (UICC), Astellas will ...
(Date:1/17/2017)... , Jan. 17, 2017 Precision medicine ... for the treatment of disease. The approach allows ... to a therapy. The approach studies the individual ... lifestyle and environment. In January 2015, Precision Medicine ... to all diseases with more than one million ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, a national, ... Franchise Development, Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide ... of top business leaders from across the globe, provides viewers an opportunity to ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... offering asset protection and financial planning services to families and business owners in ... event aimed at supporting children with developmental disabilities. , The Lakemary Center is ...
(Date:1/18/2017)... ... , ... Dr. Farhan Qureshi is an esteemed dentist who offers a full ... has two convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local Dentists ... area. This award confirms the fact that Dr. Qureshi’s patients have left highly ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... company, launched a new website for its Center for Biosimilars, announced Michael J. ... the latest developments in the field of biosimilars through thought leader interaction in, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Active Brake Technology (ABT), an innovative braking system that allows skaters of all ... addresses one of the biggest concerns of beginner and intermediate skaters – learning ...
Breaking Medicine News(10 mins):